POLBF (Poolbeg Pharma) Total Liabilities: $1.80 Mil (As of Dec. 2025)


What is Poolbeg Pharma Total Liabilities?

Poolbeg Pharma POLBF Total Liabilities is $1.80 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's Total Liabilities for the quarter that ended in Dec. 2025 was $1.80 Mil.

Poolbeg Pharma's quarterly Total Liabilities declined from Dec. 2024 ($1.23 Mil) to Jun. 2025 ($0.58 Mil) but then increased from Jun. 2025 ($0.58 Mil) to Dec. 2025 ($1.80 Mil).

Poolbeg Pharma's annual Total Liabilities declined from Dec. 2023 ($1.25 Mil) to Dec. 2024 ($1.23 Mil) but then increased from Dec. 2024 ($1.23 Mil) to Dec. 2025 ($1.80 Mil).

Poolbeg Pharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Total Liabilities Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
0.58 1.18 1.25 1.23 1.80

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only 1.25 0.71 1.23 0.58 1.80

Poolbeg Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Poolbeg Pharma's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.795+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.80

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=13.309-11.514
=1.80

Poolbeg Pharma's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.795+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.80

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=13.309-11.514
=1.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1.80 Mil mean?
Poolbeg Pharma (POLBF) has a Total Liabilities of $1.80 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Total Liabilities too high?
Poolbeg Pharma's current Total Liabilities is $1.80 Mil.
How does Poolbeg Pharma's Total Liabilities compare to VRTX and REGN?
Poolbeg Pharma's Total Liabilities of $1.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Poolbeg Pharma and its competitors. Poolbeg Pharma's current Total Liabilities is $1.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Total Liabilities of $1.80 Mil. The current Total Liabilities is $1.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Total Liabilities is $1.80 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.